Related Experiment Video
Updated: May 23, 2026
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma
Yoo-Young Lee1, Chel Hun Choi, Ha-Jeong Kim
1Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Aim:
This study was designed to investigate the prognostic value of the neutrophil:lymphocyte ratio (NLR) in cervical cancer.
Patients And Methods:
Patients with clinically staged cervical carcinoma (IB to IVA) at Samsung Medical Center, Seoul, Korea, from 1996 to 2007 were retrospectively enrolled.
Results:
We enrolled 1061 patients with cervical cancer. The median NLR was 1.9, with a range of 0.3-27.0. When the cohort was divided according to the median NLR, poorer survival outcomes were observed in the group with higher NLR (≥1.9) than in the lower NLR group (<1.9). Patients of the higher NLR group (≥1.9) were younger in age and had more advanced staged disease when compared with those of the lower NLR group (<1.9). In multivariable analysis, higher pretreatment NLR was identified as being an independent poor prognostic factor for survival.
Conclusion:
Pretreatment NLR may be a cost-effective biomarker to stratify risk of recurrence and death in patients with cervical cancer.